These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Good manufacturing practice-grade cytotoxic T lymphocytes specific for latent membrane proteins (LMP)-1 and LMP2 for patients with Epstein-Barr virus-associated lymphoma. Bollard CM; Gottschalk S; Helen Huls M; Leen AM; Gee AP; Rooney CM Cytotherapy; 2011 May; 13(5):518-22. PubMed ID: 21361747 [No Abstract] [Full Text] [Related]
5. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas. Liu Z; Savoldo B; Huls H; Lopez T; Gee A; Wilson J; Brenner MK; Heslop HE; Rooney CM Recent Results Cancer Res; 2002; 159():123-33. PubMed ID: 11785836 [TBL] [Abstract][Full Text] [Related]
6. EBV-associated lymphomas in adults. Roschewski M; Wilson WH Best Pract Res Clin Haematol; 2012 Mar; 25(1):75-89. PubMed ID: 22409825 [TBL] [Abstract][Full Text] [Related]
7. Immunotherapy with virus-specific cytotoxic T lymphocytes after organ transplantation. Lucas KG; Sun Q Pediatr Transplant; 2006 Mar; 10(2):142-4. PubMed ID: 16573596 [TBL] [Abstract][Full Text] [Related]
8. 'Off-the-shelf' allogeneic antigen-specific adoptive T-cell therapy for the treatment of multiple EBV-associated malignancies. Sinha D; Srihari S; Beckett K; Le Texier L; Solomon M; Panikkar A; Ambalathingal GR; Lekieffre L; Crooks P; Rehan S; Neller MA; Smith C; Khanna R J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589524 [TBL] [Abstract][Full Text] [Related]
9. Reduced-intensity SCT for chronic active EBV infection: excellent outcomes should trigger future investigations on how EBV-positive recipient cells are eradicated. Gottschalk S Bone Marrow Transplant; 2011 Jan; 46(1):18-9. PubMed ID: 20956953 [No Abstract] [Full Text] [Related]
10. Safety of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma. Sun Q; Burton R; Reddy V; Lucas KG Br J Haematol; 2002 Sep; 118(3):799-808. PubMed ID: 12181048 [TBL] [Abstract][Full Text] [Related]
11. The Epstein-Barr virus and the pathogenesis of lymphoma. Vockerodt M; Yap LF; Shannon-Lowe C; Curley H; Wei W; Vrzalikova K; Murray PG J Pathol; 2015 Jan; 235(2):312-22. PubMed ID: 25294567 [TBL] [Abstract][Full Text] [Related]
12. Epstein-Barr virus (EBV)-associated lymphoid lesions of the head and neck. Auerbach A; Aguilera NS Semin Diagn Pathol; 2015 Jan; 32(1):12-22. PubMed ID: 25804341 [TBL] [Abstract][Full Text] [Related]
13. Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts. O'Reilly RJ; Small TN; Papadopoulos E; Lucas K; Lacerda J; Koulova L Springer Semin Immunopathol; 1998; 20(3-4):455-91. PubMed ID: 9870257 [No Abstract] [Full Text] [Related]
14. EBV-Directed T Cell Therapeutics for EBV-Associated Lymphomas. McLaughlin LP; Gottschalk S; Rooney CM; Bollard CM Methods Mol Biol; 2017; 1532():255-265. PubMed ID: 27873282 [TBL] [Abstract][Full Text] [Related]
15. EBV specific CTL: a model for immune therapy. Rooney CM; Heslop HE; Brenner MK Vox Sang; 1998; 74 Suppl 2():497-8. PubMed ID: 9704488 [TBL] [Abstract][Full Text] [Related]